Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2023.01.10

Sai Schrödinger Research Laboratories

Sai Life Sciences inks strategic agreement to set up Schrödinger’s first dedicated offshore Research Laboratories in India

Sai Life Sciences, one of India’s fastest growing global Contract Research, Development & Manufacturing Organisations (CRO-CDMO), today announced that it has entered a 5-year strategic agreement with Schrödinger, whose physics-based computational platform is transforming the way therapeutics and materials are discovered, to set up the Sai Schrödinger Research Laboratories (SSRL) in Hyderabad, India.

Being built inside Sai Life Sciences’ R&D campus in genome valley, Hyderabad, SSRL will be a dedicated facility for integrated discovery work streams including medicinal & synthetic chemistry, in vitro biology, and process chemistry. It will access other Sai capabilities such as in vitro ADME and in vivo PK as needed. The relationship will support advancement of programs that leverage Schrödinger’s validated computational platform.

Making the announcement, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences said, “We’re truly delighted that Schrödinger has decided to partner with Sai Life Sciences to set-up their first offshore research laboratories. In many ways, this is a testimony to the advances we have made in the scale, scope and depth of our integrated drug discovery capabilities. We are very excited about working with the Schrödinger team and, guided by our brand promise, will strive to make it better together.” Scheduled to open in April 2023, SSRL will commence with about 75 staff members, across full-time-equivalents (FTEs) in Medicinal Chemistry, Biology, Process Chemistry, Analytical Chemistry, and other support staff. Recruitment has commenced for SSRL, and the open positions can be viewed here.

The Discovery business of Sai Life Sciences has been witnessing a transformative phase of growth in recent years, as is evidenced in its expanding client mix and diversity of programs. Powered by investments in talent, technology and capacity across Boston and Hyderabad, the company’s global delivery model is delivering unique value to its customers through an optimal blend of talent, speed, and cost efficiency. This journey typically starts with its exploratory biology facility in Boston, where the company works hand-in-hand with clients in real-time on early discovery biology programs that are difficult to outsource. These programs then transition to the company’s Hyderabad R&D campus, where it has consolidated its chemistry, biology and ADME-PK services in one integrated campus, allowing Sai scientists to work as teams and deliver quality data to its customers.

Share article

More News

2025.10.31

Sai Life Sciences becomes a signatory to the UN Women’s Empowerment Principles

Sai Life Sciences has joined the global community of signatories to the Women’s Empowerment Principles (WEPs) — an initiative established by UN Women and the UN Global Compact (UNGC). The WEPs serve as a global framework for businesses to advance gender equality and empower women in the workplace, marketplace, and community. By becoming a WEPs […]
Read more

2025.10.27

Sai Life Sciences set to double Process R&D capacity with new facility in Hyderabad

Hyderabad, India, October 27, 2025: Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s fastest growing Contract Research, Development, and Manufacturing Organizations (CRDMO), today announced the groundbreaking for a new CMC Process R&D Center at its integrated R&D campus in Hyderabad. Scheduled for completion by September 2026, the facility will double the […]
Read more

2025.10.08

Sai Life Sciences, Agility Life Sciences, and Centrix Pharma Solutions announce an ‘Integrated CMC Partnership’ to accelerate drug development for innovators

Manchester/Hyderabad, October 08, 2025: Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), Agility Life Sciences, and Centrix Pharma Solutions today announced the launch of an Integrated CMC Partnership designed to provide innovator biopharma companies with end-to-end Chemistry, Manufacturing and Controls (CMC) services. The collaboration combines the extensive CMC expertise of Sai Life Sciences in API […]
Read more

2025.10.06

Unlocking Chemical Frontiers: IIT Bombay Prof, Debabrata Maiti at Sai Life Sciences

As part of Sai Life Sciences’ efforts to foster knowledge exchange and bring leading voices from niche areas of science and technology to its teams, the company recently hosted Prof. Debabrata Maiti from the Indian Institute of Technology (IIT) Bombay at its R&D campus in Hyderabad for a day of scientific exchange and dialogue. The […]
Read more

2025.09.18

Sai Life Sciences opens dedicated facility for Veterinary APIs in Bidar, India

Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of Unit VI, a dedicated facility for veterinary API production, in Bidar, India. Located alongside Unit IV, the company’s flagship API manufacturing site, Unit VI has been established exclusively for veterinary APIs. The new […]
Read more